Monad 1 + Monad 2 + Monad 3 + Combination - CITI-002 (low dose) + Combination - CITI-002 (high dose)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemorrhoids
Conditions
Hemorrhoids
Trial Timeline
Apr 22, 2022 → May 17, 2023
NCT ID
NCT05348200About Monad 1 + Monad 2 + Monad 3 + Combination - CITI-002 (low dose) + Combination - CITI-002 (high dose)
Monad 1 + Monad 2 + Monad 3 + Combination - CITI-002 (low dose) + Combination - CITI-002 (high dose) is a phase 2 stage product being developed by Citius Pharmaceuticals for Hemorrhoids. The current trial status is completed. This product is registered under clinical trial identifier NCT05348200. Target conditions include Hemorrhoids.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05348200 | Phase 2 | Completed |
Competing Products
2 competing products in Hemorrhoids
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Relief Pro cream + Relief Pro rectal suppositories | Bayer | Pre-clinical | 20 |
| Hydrocortisone acetate and lidocaine hydrochloride + Placebo control + Hydrocortisone acetate + Lidocaine hydrochloride | Citius Pharmaceuticals | Phase 2 | 44 |